good ole Biotechs, ATHX down 55% PM, Athersys Announces Results From Phase 2 Study of MultiStem(R) Cell Therapy for Treatment of Ischemic Stroke http://ih.advfn.com/p.php?pid=nmona&article=66459839&symbol=ATHX